Wearable Devices Delivered Custom Touchless Technology for a Leading Global Defense Company
The solution is part of a proof of concept conducted for a leading global defense company, developed in collaboration to […]
Fundamental Global Inc. Reports First Quarter 2024 Financial Results
Mooresville, NC, May 20, 2024 (GLOBE NEWSWIRE) — Fundamental Global Inc. (Nasdaq: FGF, FGFPP) (the “Company” or “Fundamental Global”), formerly known […]
NANO Nuclear’s Executive Advisory Board Member General (ret) Wesley K. Clark, former NATO Supreme Allied Commander, Congratulates Company on Becoming the First Portable Microreactor Company to Publicly List in the U.S.
New York, N.Y., May 20, 2024 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear”), an emerging vertically […]
Presto Announces Pilot of Spanish Voice AI for Drive-Thrus
SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) — Presto Automation Inc. (“Presto” or the “Company”) (NASDAQ: PRST), one of […]
LIXTE Biotechnology Holdings Provides Update on Recent Activities
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” […]
Lead Real Estate Co., Ltd. to Participate in Nasdaq Japan IR Event on June 20, 2024
TOKYO, May 20, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE), a Japanese real estate developer of luxury residential […]
iPower’s SuperSuite Supply Chain Business Celebrates a Year of Transformative Growth
RANCHO CUCAMONGA, Calif., May 20, 2024 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and […]
Nanox to Report First Quarter and Financial Results on May 28, 2024
PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative […]
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided […]
NETSOL Technologies Reports 14% Revenue Growth and EPS of $0.03 in Fiscal Third Quarter 2024
14% increase in Total Revenues to $15.5 million in 3Q ‘24 60% increase in 3Q ‘24 Services Revenues to $7.8 […]
